Li Hua, Liu Ziquan, Xu Chuanxiang, Chen Yunyun, Zhang Jianwei, Cui Bo, Chen Xuewei, An Gaihong, She Xiaojun, Liu Hongtao, Jiang Zifeng, Wang Tianhui
Endoscopy Division, Tianjin Medical University Cancer Hospital and City Key Laboratory of Tianjin Cancer Center, Tianjin 300060;
Oncol Lett. 2013 May;5(5):1485-1490. doi: 10.3892/ol.2013.1220. Epub 2013 Feb 28.
The aim of this study was to determine the correlation of S100A4 expression with the progression, prognosis and clinical pathology of gastric cancer (GC) in young pateints. A total of 85 tumor tissues with corresponding adjacent normal tissues and 62 non-metastatic lymph nodes (LNs) with corresponding metastatic LNs were obtained from young GC patients (<40 years old) who underwent surgery between January 2001 and December 2006. The expression of S100A4 was detected by RT-PCR and immunohistochemistry. Differences in the expression of S100A4 mRNA or protein were observed among the GC tissues, matched normal gastric mucosa, non-metastatic LNs and metastatic LNs. The expression of S100A4 mRNA and protein in GC tissues and metastatic LNs was significantly higher compared with that in the matched normal gastric mucosa and non-metastatic LNs, respectively (P<0.05). The overexpression of S100A4 was significantly associated with parameters involved in tumor progression and poor prognosis, including tumor size (P=0.017), Lauren classification (P=0.002), histological classification (P= 0.010), histological differentiation (P= 0.000), Borrmann classification (P=0.020), tumor-node-metastasis (TNM) stage (P=0.000), LN metastasis (P=0.000) and distant metastasis (P=0.024). Multivariate analysis suggested that patient age (P=0.035), tumor size (P=0.002), TNM stage (P=0.001) and S100A4 upregulation (P=0.000) were independent prognostic indicators for the disease. The overexpression of S100A4 in young GC patients is significantly associated with the clinicopathological characteristics. S100A4 may be used as a biomarker to predict the progression and poor prognosis of GC in young patients.
本研究旨在确定S100A4表达与年轻胃癌（GC）患者的病情进展、预后及临床病理特征之间的相关性。从2001年1月至2006年12月接受手术的年龄小于40岁的年轻GC患者中，共获取了85例肿瘤组织及其相应的癌旁正常组织，以及62例非转移淋巴结（LNs）及其相应的转移淋巴结。通过逆转录聚合酶链反应（RT-PCR）和免疫组织化学检测S100A4的表达。观察到S100A4 mRNA或蛋白在GC组织、配对的正常胃黏膜、非转移LNs和转移LNs中的表达存在差异。与配对的正常胃黏膜和非转移LNs相比，GC组织和转移LNs中S100A4 mRNA和蛋白的表达分别显著更高（P<0.05）。S100A4的过表达与肿瘤进展和预后不良相关的参数显著相关，包括肿瘤大小（P=0.017）、劳伦分类（P=0.002）、组织学分类（P=0.010）、组织学分化（P=0.000）、博尔曼分类（P=0.020）、肿瘤-淋巴结-转移（TNM）分期（P=0.000）、LN转移（P=0.000）和远处转移（P=0.024）。多因素分析表明，患者年龄（P=0.035）、肿瘤大小（P=0.002）、TNM分期（P=0.001）和S100A4上调（P=0.000）是该疾病的独立预后指标。年轻GC患者中S100A4的过表达与临床病理特征显著相关。S100A4可作为预测年轻患者GC病情进展和预后不良的生物标志物。
